Loading...
|
Please use this identifier to cite or link to this item:
http://140.112.115.32:8080/ir/handle/987654321/901
|
| Title: | Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers |
| Authors: | Chih-Hung Lee;Shi-Bei Wu;Chien-Hui Hong;Wei-Ting Liao;Ching-Ying Wu;Gwo-Shing Chen;Yau-Huei Wei;Hsin-Su Yu |
| Contributors: | 醫學系 |
| Date: | 2011-05-01 |
| Issue Date: | 2012-02-14 15:01:31 (UTC+8) |
| Abstract: | Arsenic-induced Bowen's disease (As-BD), a cutaneous carcinoma in situ, is thought to arise from gene mutation and uncontrolled proliferation. However, how mitochondria regulate the arsenic-induced cell proliferation remains unclear. The aim of this study was to clarify whether arsenic interfered with mitochondrial biogenesis and function, leading to aberrant cell proliferation in As-BD. Skin biopsy samples from patients with As-BD and controls were stained for cytochrome c oxidase (Complex IV), measured for mitochondrial DNA (mtDNA) copy number and the expression levels of mitochondrial biogenesis–related genes, including peroxisome proliferator–activated receptor gamma coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF-1), and mitochondrial transcription factor A (mtTFA). The results showed that expression of cytochrome c oxidase, mtTFA, NRF-1, and PGC-1α was increased in As-BD compared with in healthy subjects. Treatment of primary keratinocytes with arsenic at concentrations lower than 1.0 μmol/L induced cell proliferation, along with enhanced mitochondrial biogenesis. Furthermore, we observed that the mitochondrial oxygen consumption rate and intracellular ATP level were increased in arsenic-treated keratinocytes. Blocking of mitochondrial function by oligomycin A (Complex V inhibitor) or knockdown of mtTFA by RNA interference abrogated arsenic-induced cell proliferation without affecting cyclin D1 expression. We concluded that mtTFA up-regulation, augmented mitochondrial biogenesis, and enhanced mitochondrial functions may contribute to arsenic-induced cell proliferation. Targeting mitochondrial biogenesis may help treat arsenical cancers at the stage of cell proliferation. |
| Relation: | American Journal of Pathology, 178(5), 2066-2076. https://doi.org/10.1016/j.ajpath.2011.01.056 |
| Appears in Collections: | [醫學系] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| index.html(DOI) | | 0Kb | HTML | 26 | View/Open |
|
All items in MMCIR are protected by copyright, with all rights reserved.
|
